Histone methyltransferase ASH1L primes metastases and metabolic reprogramming of macrophages in the bone niche

Chenling Meng, Kevin Lin, Wei Shi, Hongqi Teng, Xinhai Wan, Anna DeBruine, Yin Wang, Xin Liang, Javier Leo, Feiyu Chen, Qianlin Gu, Jie Zhang, Vivien Van, Kiersten L. Maldonado, Boyi Gan, Li Ma, Yue Lu () and Di Zhao ()
Additional contact information
Chenling Meng: The University of Texas MD Anderson Cancer Center
Kevin Lin: The University of Texas MD Anderson Cancer Center
Wei Shi: The University of Texas MD Anderson Cancer Center
Hongqi Teng: The University of Texas MD Anderson Cancer Center
Xinhai Wan: The University of Texas MD Anderson Cancer Center
Anna DeBruine: The University of Texas MD Anderson Cancer Center
Yin Wang: The University of Texas MD Anderson Cancer Center
Xin Liang: The University of Texas MD Anderson Cancer Center
Javier Leo: The University of Texas MD Anderson Cancer Center
Feiyu Chen: The University of Texas MD Anderson Cancer Center
Qianlin Gu: The University of Texas MD Anderson Cancer Center
Jie Zhang: The University of Texas MD Anderson Cancer Center
Vivien Van: The University of Texas MD Anderson Cancer Center
Kiersten L. Maldonado: The University of Texas MD Anderson Cancer Center
Boyi Gan: The University of Texas MD Anderson Cancer Center
Li Ma: The University of Texas MD Anderson Cancer Center
Yue Lu: The University of Texas MD Anderson Cancer Center
Di Zhao: The University of Texas MD Anderson Cancer Center

Nature Communications, 2025, vol. 16, issue 1, 1-23

Abstract: Abstract Bone metastasis is a major cause of cancer death; however, the epigenetic determinants driving this process remain elusive. Here, we report that histone methyltransferase ASH1L is genetically amplified and is required for bone metastasis in men with prostate cancer. ASH1L rewires histone methylations and cooperates with HIF-1α to induce pro-metastatic transcriptome in invading cancer cells, resulting in monocyte differentiation into lipid-associated macrophage (LA-TAM) and enhancing their pro-tumoral phenotype in the metastatic bone niche. We identified IGF-2 as a direct target of ASH1L/HIF-1α and mediates LA-TAMs’ differentiation and phenotypic changes by reprogramming oxidative phosphorylation. Pharmacologic inhibition of the ASH1L-HIF-1α-macrophages axis elicits robust anti-metastasis responses in preclinical models. Our study demonstrates epigenetic alterations in cancer cells reprogram metabolism and features of myeloid components, facilitating metastatic outgrowth. It establishes ASH1L as an epigenetic driver priming metastasis and macrophage plasticity in the bone niche, providing a bona fide therapeutic target in metastatic malignancies.

Date: 2025
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-59381-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-59381-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-59381-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().